Relay Therapeutics shares fall 1.28% intraday after HC Wainwright adjusts price target.

Relay Therapeutics, Inc. declined 1.28% in intraday trading. HC Wainwright adjusted its price target on Relay Therapeutics, a clinical-stage precision medicine company focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's Dynamo platform integrates computational and experimental approaches to drug protein targets that have previously been intractable or inadequately addressed.